10 November 2022 – Congratulations to ARS Pharmaceuticals on their five accepted poster presentations at the 2022 American College of Allergy, Asthma and Immunology Annual Scientific Meeting. PLC has supported ARS with neffy’s clinical development and Regulatory filings since the early development phases. Recently, PLC filed an NDA with the US FDA and an MAA with the EMA for neffy on behalf of ARS.
ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis
- Data from Pivotal Clinical Trials to be Presented in Five Poster Presentations at the 2022 American College of Allergy, Asthma and Immunology Annual Scientific Meeting
- Data Support New Drug Application for neffy®, Currently Under Review with U.S. FDA
